{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:10:31Z","timestamp":1789755031214,"version":"4.0.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270217"],"award-info":[{"award-number":["82270217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cellsig.2026.112857","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:05:40Z","timestamp":1788390340000},"page":"112857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["IRF4 in multiple myeloma: From molecular mechanisms to therapeutic targeting"],"prefix":"10.1016","volume":"149","author":[{"given":"Lujin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2026.112857_bb0005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3389\/fimmu.2019.01176","article-title":"Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease","volume":"10","author":"Antonczyk","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.immuni.2017.09.001","article-title":"The IRF4 gene regulatory module functions as a read-write integrator to dynamically coordinate T helper cell fate","volume":"47","author":"Krishnamoorthy","year":"2017","journal-title":"Immunity"},{"issue":"17","key":"10.1016\/j.cellsig.2026.112857_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174314","article-title":"IRF4 as an oncogenic master transcription factor","volume":"14","author":"Wong","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.cellsig.2026.112857_bb0020","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2009-07-234559","article-title":"Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis","volume":"116","author":"Jo","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0025","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1074\/jbc.M111.289728","article-title":"IRF-4 suppresses BCR\/ABL transformation of myeloid cells in a DNA binding-independent manner","volume":"287","author":"Jo","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112857_bb0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng1097-226","article-title":"Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma","volume":"17","author":"Iida","year":"1997","journal-title":"Nat. Genet."},{"issue":"7201","key":"10.1016\/j.cellsig.2026.112857_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0040","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/nar\/gkaa1287","article-title":"Structural determinants of the IRF4\/DNA homodimeric complex","volume":"49","author":"Sundararaj","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"46","key":"10.1016\/j.cellsig.2026.112857_bb0045","doi-asserted-by":"crossref","first-page":"27779","DOI":"10.1074\/jbc.M115.678789","article-title":"Structural studies of IRF4 reveal a flexible autoinhibitory region and a compact linker domain","volume":"290","author":"Remesh","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"6109","key":"10.1016\/j.cellsig.2026.112857_bb0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1126\/science.1228309","article-title":"A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes","volume":"338","author":"Glasmacher","year":"2012","journal-title":"Science"},{"issue":"7421","key":"10.1016\/j.cellsig.2026.112857_bb0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature11530","article-title":"BATF-JUN is critical for IRF4-mediated transcription in T cells","volume":"490","author":"Li","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112857_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901030","article-title":"JunB is critical for survival of T helper cells","volume":"13","author":"Hsieh","year":"2022","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.cellsig.2026.112857_bb0065","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1101\/gad.1104803","article-title":"IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development","volume":"17","author":"Lu","year":"2003","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0070","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/intimm\/dxn101","article-title":"PKC eta directs induction of IRF-4 expression and Ig kappa gene rearrangement in pre-BCR signaling pathway","volume":"20","author":"Oda","year":"2008","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.immuni.2007.12.019","article-title":"Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling","volume":"28","author":"Johnson","year":"2008","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0080","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood-2007-08-110106","article-title":"Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development","volume":"111","author":"Ma","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","article-title":"PI3K induces B-cell development and regulates B cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0090","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41590-024-01933-7","article-title":"Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development","volume":"25","author":"Fedl","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellsig.2026.112857_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779085","article-title":"IRF4 has a unique role in early B cell development and acts prior to CD21 expression to control marginal zone B cell numbers","volume":"12","author":"Ottens","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0100","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.4049\/jimmunol.2100440","article-title":"An IRF4-MYC-mTORC1 integrated pathway controls cell growth and the proliferative capacity of activated B cells during B cell differentiation in vivo","volume":"207","author":"Patterson","year":"2021","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112857_bb0110","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.4049\/jimmunol.2100747","article-title":"B cell-intrinsic IRF4 Haploinsufficiency impairs affinity maturation","volume":"207","author":"Cook","year":"2021","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112857_bb0115","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.immuni.2013.04.009","article-title":"Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4","volume":"38","author":"Ochiai","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cellsig.2026.112857_bb0120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/msb.2011.25","article-title":"An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling","volume":"7","author":"Sciammas","year":"2011","journal-title":"Mol. Syst. Biol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ni.3349","article-title":"Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation","volume":"17","author":"Minnich","year":"2016","journal-title":"Nat. Immunol."},{"issue":"18","key":"10.1016\/j.cellsig.2026.112857_bb0130","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2015-02-626176","article-title":"The forkhead transcription factor FOXP1 represses human plasma cell differentiation","volume":"126","author":"van Keimpema","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0135","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.2020005083","article-title":"Plasmablasts derive from CD23- activated B cells after the extinction of IL-4\/STAT6 signaling and IRF4 induction","volume":"137","author":"Pignarre","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0140","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s44318-024-00077-6","article-title":"Accelerated plasma-cell differentiation in Bach2-deficient mouse B cells is caused by altered IRF4 functions","volume":"43","author":"Ochiai","year":"2024","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112857_bb0145","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221292","article-title":"A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency","volume":"220","author":"Thouenon","year":"2023","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0150","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.celrep.2019.10.097","article-title":"IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis","volume":"29","author":"Low","year":"2019","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112857_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107815","article-title":"CD28 regulates metabolic fitness for long-lived plasma cell survival","volume":"31","author":"Utley","year":"2020","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0160","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2401563","article-title":"Detection of MUM1\/IRF4-IgH fusion in multiple myeloma","volume":"13","author":"Yoshida","year":"1999","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0165","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/bloodadvances.2023010218","article-title":"C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma","volume":"8","author":"Cheung","year":"2024","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.cellsig.2026.112857_bb0170","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1158\/0008-5472.CAN-16-3011","article-title":"Loss of FAM46C promotes cell survival in myeloma","volume":"77","author":"Zhu","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112857_bb0175","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1038\/ncomms10258","article-title":"The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival","volume":"7","author":"Ohguchi","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0180","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3324\/haematol.2018.191262","article-title":"DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling","volume":"104","author":"Ishiguro","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112857_bb0190","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/leu.2015.169","article-title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib","volume":"29","author":"Xie","year":"2015","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.cellsig.2026.112857_bb0195","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.cellsig.2026.112857_bb0200","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/bloodadvances.2017011601","article-title":"CD86 regulates myeloma cell survival","volume":"1","author":"Gavile","year":"2017","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112857_bb0205","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/leu.2012.326","article-title":"Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma","volume":"27","author":"Huo","year":"2013","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.cellsig.2026.112857_bb0210","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1038\/onc.2017.79","article-title":"PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4","volume":"36","author":"Ueno","year":"2017","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0215","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1093\/nar\/gkx327","article-title":"Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell","volume":"45","author":"Kassambara","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0220","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/CAD.0000000000001378","article-title":"Circ_0005615 contributes to the progression and Bortezomib resistance of multiple myeloma by sponging miR-185-5p and upregulating IRF4","volume":"33","author":"Fu","year":"2022","journal-title":"Anti-Cancer Drugs"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0225","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s12276-025-01587-x","article-title":"RNA N(6)-methyladenosine reader protein YTHDF1 promotes plasma cell differentiation via IRF4 regulation in systemic lupus erythematosus","volume":"57","author":"Lu","year":"2025","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0230","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1038\/s41423-020-00567-7","article-title":"USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"38","key":"10.1016\/j.cellsig.2026.112857_bb0235","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1038\/s41388-025-03513-x","article-title":"LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","article-title":"Acetyl-CoA Synthetase 2: a critical linkage in obesity-induced tumorigenesis in myeloma","volume":"33","author":"Li","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2026.112857_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-76595-0","article-title":"Adipocyte-derived \u03b2-hydroxybutyrate confers metabolic resilience in multiple myeloma","author":"Song","year":"2026","journal-title":"Nat. Commun."},{"issue":"6660","key":"10.1016\/j.cellsig.2026.112857_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/science.adh5021","article-title":"The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation","volume":"381","author":"Gu","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2026.112857_bb0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma-biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112857_bb0260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1074-7613(00)80166-1","article-title":"Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52","volume":"12","author":"Mamane","year":"2000","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood.2025028615","article-title":"Check the brakes on IRF4!","volume":"146","author":"Pawlyn","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003096","article-title":"Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells","volume":"23","author":"Oikonomidi","year":"2025","journal-title":"PLoS Biol."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112857_bb0275","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/bloodadvances.2017008847","article-title":"Hypoxia-inducible KDM3A addiction in multiple myeloma","volume":"2","author":"Ikeda","year":"2018","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0290","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1111\/cas.15087","article-title":"Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma","volume":"112","author":"Ikeda","year":"2021","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0300","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","article-title":"Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma","volume":"12","author":"Alvarez-Benayas","year":"2021","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.cellsig.2026.112857_bb0305","doi-asserted-by":"crossref","first-page":"11914","DOI":"10.1158\/0008-5472.CAN-07-1868","article-title":"Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown","volume":"67","author":"Lin","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0310","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","article-title":"The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival","volume":"35","author":"Fedele","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0315","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2013.02.017","article-title":"Control of autophagic cell death by caspase-10 in multiple myeloma","volume":"23","author":"Lamy","year":"2013","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cellsig.2026.112857_bb0320","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1158\/2643-3230.BCD-24-0223","article-title":"IRF4 promotes immune evasion and shapes the tumor microenvironment in follicular lymphoma","volume":"6","author":"Dasari","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/v17070885","article-title":"IRF4 mediates immune evasion to facilitate EBV transformation","volume":"17","author":"Wang","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.cellsig.2026.112857_bb0330","article-title":"Regulatory effects of IRF4 on immune cells in the tumor microenvironment","volume":"14","author":"Lu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.14366","article-title":"Interferon regulatory factor 4: an alternative marker for plasma cells in Daratumumab-treated patients with multiple myeloma","volume":"47","author":"Yang","year":"2025","journal-title":"Int. J. Lab. Hematol."},{"issue":"15","key":"10.1016\/j.cellsig.2026.112857_bb0340","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1111\/febs.16068","article-title":"The immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells","volume":"289","author":"Perini","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.cellsig.2026.112857_bb0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcancer.2023.01.002","article-title":"Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors","volume":"89","author":"Ahmad","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0350","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer - from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112857_bb0355","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112857_bb0360","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.cellsig.2026.112857_bb0365","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/bloodadvances.2022007155","article-title":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase","volume":"7","author":"Harada","year":"2023","journal-title":"Blood Adv."},{"issue":"48","key":"10.1016\/j.cellsig.2026.112857_bb0370","doi-asserted-by":"crossref","first-page":"79064","DOI":"10.18632\/oncotarget.12594","article-title":"Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors","volume":"7","author":"Bat-Erdene","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2026.112857_bb0375","first-page":"24","article-title":"Disordered histone methylation in hematological malignancies the CASE of UTX\/KDM6A","volume":"129","author":"Licht","year":"2018","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112857_bb0380","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41416-018-0025-x","article-title":"DNMTi\/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells","volume":"118","author":"Bruyer","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.cellsig.2026.112857_bb0385","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0395","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112857_bb0400","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3324\/haematol.2017.164632","article-title":"The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling","volume":"102","author":"D\u00edaz","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112857_bb0405","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.cellsig.2026.112857_bb0410","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112857_bb0415","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jir.2014.0125","article-title":"Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma","volume":"35","author":"Yoo","year":"2015","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.cellsig.2026.112857_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117240","article-title":"Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma","volume":"285","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2026.112857_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41589-026-02228-8","article-title":"Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma","author":"Agius","year":"2026","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112857_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cellsig.2026.112857_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139186","article-title":"Antisense oligonucleotides-based approaches for the treatment of multiple myeloma","volume":"291","author":"Oprea","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cellsig.2026.112857_bb0445","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT146","article-title":"Safety, tolerability and molecular correlates of the IRF4-targeted antisense oligonucleotide frenlosirsen in patients with relapsed\/refractory multiple myeloma: a phase 1a dose escalation trial [abstract]","volume":"85","author":"Tong","year":"2025","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0450","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/leu.2015.124","article-title":"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo","volume":"29","author":"Morelli","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112857_bb0455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2006.07.009","article-title":"Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation","volume":"25","author":"Sciammas","year":"2006","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0460","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/ni.2710","article-title":"The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells","volume":"14","author":"Man","year":"2013","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.cellsig.2026.112857_bb0465","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112857_bb0470","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112857_bb0475","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112857_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.cellsig.2026.112857_bb0485","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112857_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108087","article-title":"The transcription factor IRF4 determines the anti-tumor immunity of CD8(+) T cells","volume":"26","author":"Yan","year":"2023","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112857_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114401","article-title":"IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression","volume":"43","author":"Hirsch","year":"2024","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112857_bb0500","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellsig.2026.112857_bb0505","doi-asserted-by":"crossref","first-page":"1185618","DOI":"10.3389\/fimmu.2023.1185618","article-title":"IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities","volume":"14","author":"Harrer","year":"2023","journal-title":"Front. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.cellsig.2026.112857_bb0510","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00005-016-0442-6","article-title":"Cereblon and IRF4 variants affect risk and response to treatment in multiple myeloma","volume":"64","author":"Butrym","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:42Z","timestamp":1789753422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826005152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":102,"alternative-id":["S0898656826005152"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112857","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IRF4 in multiple myeloma: From molecular mechanisms to therapeutic targeting","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112857"}}